Legend Biotech (LEGN) announced the appointment of Alan Bash as the Company’s President of CARVYKTI. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI, overseeing Legend Biotech’s commercial, technical operations, and quality functions of the franchise. Bash served as CEO for two oncology-focused biotech companies, most recently at ZielBio, and before that, as President and CEO at Checkmate Pharmaceuticals
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech participates in a conference call with JPMorgan
- Legend Biotech Faces Financial Restructuring Amid Voting Changes
- Legend Biotech’s AGM Highlights Shareholder Confidence
- 3 Best Stocks to Buy Now, 10/16/2024, According to Top Analysts
- Legend Biotech weakness a buying opportunity, says Barclays